ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 50 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.21 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $260,125 | -64.3% | 743,215 | 0.0% | 0.20% | -57.3% |
| Q1 2024 | $728,351 | +47.6% | 743,215 | 0.0% | 0.47% | +274.4% |
| Q4 2023 | $493,495 | -11.1% | 743,215 | 0.0% | 0.12% | -43.4% |
| Q3 2023 | $555,182 | -23.1% | 743,215 | 0.0% | 0.22% | -7.1% |
| Q2 2023 | $721,662 | +11.1% | 743,215 | 0.0% | 0.24% | -10.9% |
| Q1 2023 | $649,570 | -8.3% | 743,215 | 0.0% | 0.27% | -13.3% |
| Q4 2022 | $708,284 | -13.4% | 743,215 | 0.0% | 0.31% | +3.0% |
| Q3 2022 | $818,000 | -9.0% | 743,215 | 0.0% | 0.30% | -34.0% |
| Q2 2022 | $899,000 | -52.3% | 743,215 | -15.2% | 0.45% | -49.2% |
| Q1 2022 | $1,885,000 | -81.9% | 876,548 | 0.0% | 0.89% | -79.5% |
| Q4 2021 | $10,405,000 | -23.5% | 876,548 | 0.0% | 4.35% | -9.4% |
| Q3 2021 | $13,595,000 | -23.9% | 876,548 | 0.0% | 4.80% | -31.8% |
| Q2 2021 | $17,873,000 | -10.3% | 876,548 | 0.0% | 7.04% | +10.1% |
| Q1 2021 | $19,933,000 | -17.8% | 876,548 | 0.0% | 6.40% | -20.0% |
| Q4 2020 | $24,237,000 | – | 876,548 | – | 7.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,457,937 | $510,278 | 0.66% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $260,125 | 0.20% |
| Vivo Capital, LLC | 3,547,030 | $1,241,461 | 0.12% |
| Opaleye Management Inc. | 1,260,000 | $441,000 | 0.10% |
| EcoR1 Capital, LLC | 6,389,468 | $2,236,314 | 0.07% |
| Deep Track Capital, LP | 6,102,770 | $2,135,970 | 0.06% |
| TANG CAPITAL MANAGEMENT LLC | 1,650,000 | $577,500 | 0.06% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 655,515 | $229,430 | 0.05% |
| Newtyn Management, LLC | 719,287 | $251,750 | 0.05% |
| ARMISTICE CAPITAL, LLC | 7,256,410 | $2,539,744 | 0.03% |